Thus, KRASG12Ci in combination with PLK1i exhibited synergistic cytotoxic effects and abrogate resistance in KRASG12C-mutant cancer cells by concomitant suppression of both ERK-dependent and -independent c-Myc expression. Here, MYC is linked to cancer.